Trial Profile
Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 12 May 2021 Status changed from active, no longer recruiting to completed.
- 18 May 2020 Planned End Date changed from 1 Nov 2020 to 1 May 2021.
- 18 Apr 2019 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.